全文获取类型
收费全文 | 8829篇 |
免费 | 688篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 186篇 |
妇产科学 | 147篇 |
基础医学 | 1178篇 |
口腔科学 | 134篇 |
临床医学 | 1275篇 |
内科学 | 1774篇 |
皮肤病学 | 66篇 |
神经病学 | 703篇 |
特种医学 | 406篇 |
外科学 | 1007篇 |
综合类 | 99篇 |
一般理论 | 3篇 |
预防医学 | 1128篇 |
眼科学 | 105篇 |
药学 | 658篇 |
中国医学 | 64篇 |
肿瘤学 | 555篇 |
出版年
2023年 | 45篇 |
2022年 | 67篇 |
2021年 | 148篇 |
2020年 | 111篇 |
2019年 | 141篇 |
2018年 | 205篇 |
2017年 | 158篇 |
2016年 | 163篇 |
2015年 | 225篇 |
2014年 | 291篇 |
2013年 | 439篇 |
2012年 | 661篇 |
2011年 | 681篇 |
2010年 | 383篇 |
2009年 | 344篇 |
2008年 | 602篇 |
2007年 | 617篇 |
2006年 | 559篇 |
2005年 | 541篇 |
2004年 | 480篇 |
2003年 | 423篇 |
2002年 | 442篇 |
2001年 | 122篇 |
2000年 | 127篇 |
1999年 | 130篇 |
1998年 | 78篇 |
1997年 | 68篇 |
1996年 | 68篇 |
1995年 | 70篇 |
1994年 | 56篇 |
1993年 | 61篇 |
1992年 | 64篇 |
1991年 | 57篇 |
1990年 | 75篇 |
1989年 | 56篇 |
1988年 | 49篇 |
1987年 | 49篇 |
1986年 | 54篇 |
1985年 | 41篇 |
1984年 | 40篇 |
1983年 | 36篇 |
1982年 | 30篇 |
1981年 | 35篇 |
1980年 | 29篇 |
1979年 | 36篇 |
1978年 | 23篇 |
1976年 | 31篇 |
1975年 | 22篇 |
1970年 | 22篇 |
1966年 | 33篇 |
排序方式: 共有9523条查询结果,搜索用时 15 毫秒
991.
Lack of effect of dirithromycin on theophylline pharmacokinetics in healthy volunteers. 总被引:2,自引:0,他引:2
Twelve healthy volunteers were enrolled in an open-label, randomized, crossover study. Subjects received single doses of theophylline (5 mg/kg) alone and after a 10 day course of dirithromycin (two 250 mg tablets od). The study phases were separated by a 3 week washout period. Serum samples were collected before and for 24 h after theophylline doses. Serum theophylline concentrations were measured via a validated immunoassay system and the data were modelled via non-compartmental analysis. When the control phase (i.e. no dirithromycin) was compared with the treatment phase (i.e. with dirithromycin), theophylline exposures as measured by AUC0-->infinity were not significantly different: 141.7+/-25.9 and 136.4+/-33.1 mg x h/L respectively (P = 0.16). No significant changes in other theophylline pharmacokinetic parameters were evident. These results indicate that theophylline can be safely co-administered with dirithromycin. 相似文献
992.
993.
Alma Tostmann Charles M. Mtabho Hadija H. Semvua Jossy van den Boogaard Gibson S. Kibiki Martin J. Boeree Rob E. Aarnoutse 《Antimicrobial agents and chemotherapy》2013,57(7):3208-3213
East Africa has a high tuberculosis (TB) incidence and mortality, yet there are very limited data on exposure to TB drugs in patients from this region. We therefore determined the pharmacokinetic characteristics of first-line TB drugs in Tanzanian patients using intensive pharmacokinetic sampling. In 20 adult TB patients, plasma concentrations were determined just before and at 1, 2, 3, 4, 6, 8, 10, and 24 h after observed drug intake with food to estimate the areas under the curve from 0 to 24 h (AUC0–24) and peak plasma concentrations (Cmax) of isoniazid, rifampin, pyrazinamide, and ethambutol. Acetylator status for isoniazid was assessed phenotypically using the isoniazid elimination half-life and the acetylisoniazid/isoniazid metabolic ratio at 3 h postdose. The geometric mean AUC0–24s were as follows: isoniazid, 11.0 h · mg/liter; rifampin, 39.9 h · mg/liter; pyrazinamide, 344 h · mg/liter; and ethambutol, 20.2 h · mg/liter. The Cmax was below the reference range for isoniazid in 10/19 patients and for rifampin in 7/20 patients. In none of the patients were the Cmaxs for pyrazinamide and ethambutol below the reference range. Elimination half-life and metabolic ratio of isoniazid gave discordant phenotyping results in only 2/19 patients. A substantial proportion of patients had an isoniazid and/or rifampin Cmax below the reference range. Intake of TB drugs with food may partly explain these low drug levels, but such a drug intake reflects common practice. The finding of low TB drug concentrations is concerning because low concentrations have been associated with worse treatment outcome in several other studies. 相似文献
994.
995.
996.
997.
998.
The colon provides a plethora of therapeutic opportunities. There are multiple disease targets, drug molecules, and colon-specific delivery systems to be explored. Clinical studies highlight the potential for systemic delivery via the colon, and the emerging data on the levels of cell membrane transporters and metabolic enzymes along the gut could prove advantageous for this. Often efflux transporters and metabolic enzyme levels are lower in the colon, suggesting a potential for improved bioavailability of drug substrates at this site. The locoregional distribution of multiple metabolic enzymes (including cytochromes), efflux transporters (including P-glycoprotein and breast cancer resistance proteins), and influx transporters (including the solute carrier family) along the intestine is summarized. Local delivery to the colonic mucosa remains a valuable therapeutic option. New therapies that target inflammatory mediators could improve the treatment of inflammatory bowel disease, and old and new anticancer molecules could, when delivered topically, prove to be beneficial adjuncts to the current systemic or surgical treatments. New issues such as pharmacogenomics, chronotherapeutics, and the delivery of prebiotics and probiotics are also discussed in this review. Targeting drugs to the colon utilizes various strategies, each with their advantages and flaws. The most promising systems are considered in the light of the physiological data which influence their in vivo behavior. 相似文献
999.
1000.